Mergers and acquisitions – Page 3
-
BusinessSensing the sweet spot
Ziylo’s selective glucose-binding molecule could open doors to smart insulin for diabetes
-
BusinessNovartis to cut over 2000 jobs
Move exemplifies a wave of manufacturing cuts as pharma moves to more high-value, specialised medicines
-
BusinessTakeda set to swallow Shire
Shire’s US revenue and rare diseases portfolio grab Japanese firm’s attention
-
BusinessNovartis’ $8.7bn AveXis deal shows gene therapy appeal
Acquisition indicates the value of potentially permanent cures for inherited diseases
-
BusinessAkzoNobel sells off specialty chemicals arm in €10bn deal
Private equity firm Carlyle sees off several other bidders
-
ArticlePharma and academia: a recipe for success
More big pharmaceutical companies are collaborating with universities
-
BusinessIndian court seizes former Ranbaxy owners’ assets
Daiichi Sankyo inches closer to recovering money from Singh brothers
-
BusinessDowDupont names its three new separate businesses
Corteva Agriscience, Dow and DuPont will be what DowDuPont calls the three independent companies it will spin-off by June 2019
-
BusinessBMS stimulates cancer drug hopes with giant collaboration
Immunooncology pioneer will pay up to $3.6bn in hope Nektar drug will help non-responders
-
BusinessSanofi enters M&A bonanza
French drugmaker strengthens rare diseases portfolio with blood disorder purchases
-
BusinessCelgene takes a punt on M&A
Cancer specialist bags Juno therapeutics and Impact Biomedicines
-
BusinessChemical industry roundup 2017
Economic and political pressure is encouraging industry to become more specialised as certain sectors consolidate
-
BusinessPharmaceuticals roundup 2017
Political influence has strongly shaped industry activity in the past year
-
BusinessDuPont and Sumitomo link up for seed treatments
Firms will collaborate to develop and commercialise seed-applied technologies
-
BusinessBayer forms cancer-drug partnership with Loxo
Alliance could see Loxo net up to $1.55bn in upfront and milestone payments
-
BusinessChina moves in on US shale gas
Alaska and West Virginia have welcomed investment from Chinese entities to develop US shale resources
-
BusinessValeant relinquishes female libido drug
Struggling firm is returning Sprout Pharmaceuticals subsidiary to original shareholders to resolve dispute over marketing
-
BusinessGenerics firms Amneal and Impax to merge
Deal continues consolidation trend, based on portfolio expansion and simplifying supply chains
-
BusinessNovartis to buy AAA for radioligand cancer drugs
$3.9bn deal follows European approval of Advanced Accelerator Applications’ first-in-class radionuclide drug Lutathera
-
BusinessLilly and CureVac to collaborate on mRNA cancer vaccines
Deal could see CureVac net up to $1.8 billion in upfront and milestone payments